LE WE PMID CA
Leukemia (acute myeloic)1584Leukaemie (akute myeloische)

AF10

AML1 ETO fusion oncogene

Amonafide AS1413 ttIntercalator

Apoptosis

ARRY520 ttKSP

ASXL1

Azacitidine

AZD1152 ttAuroraB

AZD6244 ttMEK

BehenoylaraC ttProdrugAraC

Bim

BiP GRP78

Calicheamicin

CALM

Cbl

Cell stress (ER stress)

Chloroma

Clofarabine

Cytosine arabinoside

DAPK1

Decitabine

Dnmt

Down s syndrome

eIF2A

eIF4E

Elacytarabine

ERS UFR (Apoptosis)

Flavopiridole

FLT3

Flt3ITD

GADD34

Gemtuzumab ozogamicin ttCD33

HDAC2

HDAC6

IDH1 Isocitrate dehydrogenase1 NADP soluble

IDH2

IKZF1

Interleukin24 MDA7

IRE1alpha

JAK2V617F

KSP Kinesin spindle protein

Leukemia (acute lymphoblastic)

Leukemia (acute myeloic)

Leukemia (acute promyelocytic)

Leukemia (chronic myelomonocytic leukaemia)

Lymphoproliferative disorders (Classification)

Mastocytosis

MCL1

MN1

MPL

MTOR

Myelodysplastic syndrome

Myeloid sarcoma

Myeloproliferative syndromes

Neoplasia (Fusion oncogenes)

Neoplasia (Minimal residual disease)

NFKB

Noxa

Nucleophosmin

Ribavirin

Sapacitabine

Sorafenib

TAK1

Terameprocol ttSurvivin ttCDK1

TET2

Tipifarnib

Voreloxin ttIntercalator

Vorinostat ttHDAC

1996  
1
2008  
2
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.
[19707379] Biologics 2(3): 491-500 (2008)
2008  
3
Clofarabine: in search of combinations for the treatment of patients with high-risk acute myeloid leukemia.
[18780321] Cancer 113(8): 1995-8 (2008)
2008  
4
Monitoring of minimal residual disease in acute myeloid leukemia.
[18000811] Cancer 112(1): 4-16 (2008)
2007  
5
Progress in the treatment of acute myeloid leukemia.
[17786921] Cancer 110(9): 1900-10 (2007)
2006  
6
Acute myeloid leukemia: epidemiology and etiology.
[17019734] Cancer 107(9): 2099-107 (2006)
2004  
7
New agents in acute myeloid leukemia and other myeloid disorders.
[14745859] Cancer 100(3): 441-54 (2004)
2001  
8
Therapeutic options for acute myelogenous leukemia.
[11571716] Cancer 92(5): 1059-73 (2001)
2001  
9
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
[11410481] Clin Cancer Res 7(6): 1490-6 (2001)
2009  
10
Immunotherapy of acute myeloid leukemia: current approaches.
[19289488] Oncologist 14(3): 240-52 (2009)
2009  
11
Acute myelogenous leukemia in older adults.
[19282349] Oncologist 14(3): 222-32 (2009)
2007  
12
Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
[17405900] Oncologist 12(3): 341-55 (2007)
2007  
13
Recent developments in acute myelogenous leukemia therapy.
[18039635] Oncologist 12 Suppl 2(-): 14-21 (2007)
2001  
14
Realistic pathologic classification of acute myeloid leukemias.
[11293903] Am J Clin Pathol 115(4): 552-60 (2001)
2005  
15
Drug therapy for acute myeloid leukemia.
[15870183] Blood 106(4): 1154-63 (2005)
1996  
16
Treatment of myelogenous leukemia: current status and investigational options.
[8605319] Blood 87(8): 3069-81 (1996)
1987  
17
Acute myelogenous leukemia: recent advances in therapy.
[3555647] Blood 69(6): 1551-62 (1987)
2008  
18
Molecular genetic pathways as therapeutic targets in acute myeloid leukemia.
[19074117] Hematology Am Soc Hematol Educ Program -(-): 400-11 (2008)
2008  
19
Acute myeloid leukemia: the challenge of capturing disease variety.
[19074046] Hematology Am Soc Hematol Educ Program -(-): 1-11 (2008)
2007  
20
2007  
21
Implication of the molecular characterization of acute myeloid leukemia.
[18024659] Hematology Am Soc Hematol Educ Program -(-): 412-9 (2007)
2005  
22
The molecular pathology of acute myeloid leukemia.
[16304371] Hematology Am Soc Hematol Educ Program -(-): 137-42 (2005)
2004  
23
2003  
24
Acute myeloid leukemia and acute promyelocytic leukemia.
[14633778] Hematology Am Soc Hematol Educ Program -(-): 82-101 (2003)
2002  
25
2001  
26
2006  
27
2009  
28
Myeloid sarcoma: extramedullary manifestation of myeloid disorders.
[19687319] Am J Clin Pathol 132(3): 426-37 (2009)
2010  
29
A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia.
[20538803] Blood 116(13): 2205-14 (2010)
2007  
30
Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.
[17412887] Blood 110(3): 799-805 (2007)
2007  
31
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
[17008539] Blood 109(3): 874-85 (2007)
2010  
32
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
[19880497] Blood 115(3): 453-74 (2010)
2010  
33
Allogeneic stem cell transplantation for acute myeloid leukemia.
[20513804] Haematologica 95(6): 857-9 (2010)
2002  
34
Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity.
[11869944] Haematologica 87(3): 306-19 (2002)
2011  
35
Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum.
[21454879] Haematologica 96(4): 491-3 (2011)
2010  
36
Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help.
[20378574] Haematologica 95(4): 529-34 (2010)
2008  
37
Molecular characterization of acute myeloid leukemia.
[18591623] Haematologica 93(7): 976-82 (2008)
2003  
38
Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature.
[12935987] Haematologica 88(8): ECR28 (2003)
2008  
39
Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives.
[19050066] Haematologica 93(12): 1769-72 (2008)
2007  
40
Deregulation of apoptosis in acute myeloid leukemia.
[17229639] Haematologica 92(1): 81-94 (2007)
2010  
41
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.
[19951971] Haematologica 95(5): 819-28 (2010)
2004  
42
Childhood and adolescent lymphoid and myeloid leukemia.
[15561680] Hematology Am Soc Hematol Educ Program -(-): 118-45 (2004)
2009  
43
Independent prognostic factors for AML outcome.
[20008224] Hematology Am Soc Hematol Educ Program -(-): 385-95 (2009)
2009  
44
Optimal induction and post-remission therapy for AML in first remission.
[20008225] Hematology Am Soc Hematol Educ Program -(-): 396-405 (2009)
2009  
45
What is the role of reduced-intensity transplantation in the treatment of older patients with AML?
[20008226] Hematology Am Soc Hematol Educ Program -(-): 406-13 (2009)
2010  
46
New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues.
[21034669] Discov Med 10(53): 281-92 (2010)
2009  
47
Structural and functional alterations of FLT3 in acute myeloid leukemia.
[19549778] Clin Cancer Res 15(13): 4263-9 (2009)
2010  
48
Questions regarding frontline therapy of acute myeloid leukemia.
[20623787] Cancer 116(21): 4896-901 (2010)
2006  
49
High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.
[16721819] Cancer 107(1): 116-24 (2006)
2010  
50
Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
[20507806] Health Technol Assess 14 Suppl 1(-): 69-74 (2010)
2005  
51
Topics in pediatric leukemia--acute myeloid leukemia.
[16369325] MedGenMed 7(1): 20 (2005)
2009  
52
Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.
[19503782] Clin Interv Aging 4(-): 197-205 (2009)
2010  
53
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
[20671809] Oncotarget 1(2): 89-103 (2010)
2011  
54
Targeting mTOR for the treatment of AML. New agents and new directions.
[21680954] Oncotarget 2(6): 510-7 (2011)
2007  
55
Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation.
[17125917] Cancer Lett 251(2): 179-86 (2007)
2010  
56
Melanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress.
[20858700] Mol Pharmacol 78(6): 1096-104 (2010)
2012  
57
A noncanonical Flt3ITD/NF-kappaB signaling pathway represses DAPK1 in acute myeloid leukemia.
[22096027] Clin Cancer Res 18(2): 360-9 (2012)
2007  
58
2009  
59
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
[19652076] J Clin Oncol 27(26): 4392-7 (2009)
2011  
60
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.
[21453545] J Hematol Oncol 4(-): 13 (2011)
2011  
61
Current findings for recurring mutations in acute myeloid leukemia.
[21917154] J Hematol Oncol 4(-): 36 (2011)
2010  
62
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights.
[20416083] J Hematol Oncol 3(-): 17 (2010)
2009  
63
Novel postremission strategies in adults with acute myeloid leukemia.
[19468272] Curr Opin Hematol 16(2): 105-11 (2009)
2010  
64
2010  
65
Will newer tyrosine kinase inhibitors have an impact in AML?
[21130412] Best Pract Res Clin Haematol 23(4): 489-94 (2010)
2009  
66
2012  
67
Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.
[21904549] J Oncol 2012(-): 128608 (2012)
2007  
68
2009  
69
New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.
[19679009] Curr Oncol Rep 11(5): 346-52 (2009)
2010  
70
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
[20428194] Leukemia 24(6): 1128-38 (2010)
2008  
71
The role of CALM-AF10 gene fusion in acute leukemia.
[18094714] Leukemia 22(4): 678-85 (2008)
2010  
72
Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature.
[20445327] Korean J Lab Med 30(2): 117-21 (2010)
2010  
73
Exploiting cellular pathways to develop new treatment strategies for AML.
[20056334] Cancer Treat Rev 36(2): 142-50 (2010)
2010  
74
Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?
[20629523] Leuk Lymphoma 51(10): 1805-15 (2010)
2009  
75
Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.
[19569254] Hematol Oncol 27(4): 171-81 (2009)
2010  
76
Recent advances in the treatment of acute myeloid leukemia.
[20798782] F1000 Med Rep 2(-): 55 (2010)
2011  
77
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
[21779483] Genes Cancer 2(2): 95-107 (2011)
2011  
78
Recurrent neurotropic chloroma: report of a case and review of the literature.
[21200413] Adv Hematol 2011(): 854240 (2011)
2010  
79
Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition.
[21417999] Biochemistry (Mosc) 75(13): 1650-66 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia